Bridges Investment Management Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 38.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 35,294 shares of the company’s stock after buying an additional 9,815 shares during the period. Bridges Investment Management Inc.’s holdings in Eli Lilly and Company were worth $40,838,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also made changes to their positions in the business. BlackRock Inc. raised its position in shares of Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares in the last quarter. State Street Corp boosted its holdings in Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Bank of America Corp DE acquired a new position in Eli Lilly and Company in the second quarter valued at approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after purchasing an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC increased its stake in Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after purchasing an additional 400,538 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.
Eli Lilly and Company Stock Down 1.3%
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the prior year, the business earned $7.02 EPS. Eli Lilly and Company’s quarterly revenue was up 38.6% compared to the same quarter last year. Sell-side analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current year.
Eli Lilly and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.
More Eli Lilly and Company News
Investors following LLY have been watching these news items:
- Positive Sentiment: New ObesityWeek 2026 results for Lilly’s obesity and cardiometabolic portfolio—including retatrutide, EloraTZP and Foundayo—showed benefits across weight loss and related conditions such as blood-sugar control, sleep apnea and knee osteoarthritis. The breadth of findings supports Lilly’s effort to build a broader cardiometabolic franchise. Article: Positive Trial Results Could Be A Big Moment For Eli Lilly Stock
- Positive Sentiment: Royal Bank of Canada reaffirmed its “outperform” rating and $1,600 price target, implying analyst confidence in further upside. Royal Bank of Canada recommendations
- Neutral Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to add experimental treatments for rare blood cancers. The acquisition broadens its oncology pipeline, but clinical and regulatory milestones will determine the ultimate value and cost. Article: Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Portfolio
Analyst Upgrades and Downgrades
LLY has been the topic of a number of research analyst reports. Barclays raised their price objective on shares of Eli Lilly and Company from $1,400.00 to $1,550.00 and gave the stock an “overweight” rating in a report on Monday. The Goldman Sachs Group restated a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research report on Friday. HSBC increased their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. Finally, Bank of America reiterated a “buy” rating and set a $1,497.00 price target on shares of Eli Lilly and Company in a research note on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,422.00.
Read Our Latest Report on Eli Lilly and Company
Eli Lilly and Company Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Read More
- Five stocks we like better than Eli Lilly and Company
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
